Silence Therapeutics PLC Form 4 insider transactions

Richard Ian Griffiths, a 10% owner of Silence Therapeutics plc, reported multiple transactions in common stock on August 10, 2026.

Richard Ian Griffiths, a director at Silence Therapeutics plc, reported the sale of American Depositary Shares (ADS) and ordinary shares across multiple transactions in late June and early July 2026.

Silence Therapeutics director Richard Ian Griffiths reported internal transfers of American Depositary Shares, maintaining his overall beneficial ownership.

Silence Therapeutics plc Director James Ede-Golightly was granted 90,000 share options with an exercise price of $2.05, vesting over one year.

Silence Therapeutics plc Director Timothy McInerney acquired 90,000 share options with an exercise price of $2.05, vesting over one year.

Silence Therapeutics plc's EVP and Chief R&D Officer, Steven J. Romano, was granted 300,000 employee share options with an exercise price of $2.05.

Silence Therapeutics plc's Chief Financial Officer, Rhonda Lynette Hellums, was granted 375,000 employee share options with an exercise price of $2.05.

Silence Therapeutics plc Director David Lemus was granted 90,000 share options with an exercise price of $2.05, vesting over one year.

Silence Therapeutics plc's Interim PEO, Iain Ross, was granted 900,000 employee share options with an exercise price of $2.08, vesting over one year.

Silence Therapeutics plc Director James Ede-Golightly was granted 90,000 share options with an exercise price of $2.15, vesting over one year.

A director and 10% owner of Silence Therapeutics plc has pre-disclosed plans to significantly increase their indirect beneficial ownership through future purchases of American Depositary Shares.

Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc, acquired additional American Depositary Shares on July 29 and July 30, 2025, increasing his indirect beneficial ownership.

Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc, acquired additional American Depositary Shares on July 21 and 22, 2025, increasing his indirect beneficial ownership.

Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc, has significantly increased his beneficial ownership through recent purchases of American Depositary Shares.

Richard Ian Griffiths, a Director and 10% Owner of Silence Therapeutics plc, has significantly increased his direct beneficial ownership through multiple American Depositary Share acquisitions in July 2025.

Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc, has substantially increased his beneficial ownership through multiple purchases of American Depositary Shares in late June 2025.

Richard Ian Griffiths, a Director and 10% Owner of Silence Therapeutics plc, has significantly increased his beneficial ownership through multiple purchases of American Depositary Shares (ADS) totaling 82,606 ADS over three days in June 2025.

Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc, has reported the acquisition of 70,448 American Depositary Shares across two transactions in June 2025, increasing his direct beneficial ownership.

Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc, has acquired 39,305 American Depositary Shares, increasing his direct beneficial ownership.

Richard Ian Griffiths, a Director and 10% Owner of Silence Therapeutics plc, has significantly increased his direct beneficial ownership through multiple purchases of American Depositary Shares (ADS) totaling 85,838 ADS.

Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc, has significantly increased his beneficial ownership through the acquisition of American Depositary Shares on May 22 and May 23, 2025.

Director Richard Ian Griffiths reports transactions involving Silence Therapeutics plc American Depositary Shares, increasing his beneficial ownership.

Director Timothy McInerney of Silence Therapeutics plc acquired 48,000 share options on May 5, 2025, according to a Form 4 filing with the SEC.

Director Richard Ian Griffiths of Silence Therapeutics plc reports selling American Depositary Shares (ADS) on May 13 and 14, 2025.

Director Richard Ian Griffiths reports changes in beneficial ownership of Silence Therapeutics plc shares through recent transactions.

Director Richard Ian Griffiths reports acquiring Silence Therapeutics shares through American Depositary Shares (ADS) on April 30, 2025, and May 1, 2025.

Director Richard Ian Griffiths reports acquiring additional American Depositary Shares (ADS) of Silence Therapeutics plc on April 28 and 29, 2025.

Director Richard Ian Griffiths reports acquiring Silence Therapeutics shares through American Depositary Shares (ADS) on April 24 and 25, 2025.

Director Richard Ian Griffiths reports purchasing Silence Therapeutics plc shares through American Depositary Shares (ADS) on April 22 and 23, 2025.

Director Richard Ian Griffiths reports purchasing Silence Therapeutics plc shares in two transactions on April 17 and April 21, 2025.